Karakashev S.; Zhu H.; Yokoyama Y.; Zhao B.; Fatkhutdinov N.; Kossenkov A.; Wilson A.; Simpkins F.; Speicher D.; Khabele D.; Bitler B.; Zhang R.
(2017)
© 2017 The Author(s) PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here, we show the synergy of BET bromodomain ...